MIAMI, FL / ACCESSWIRE / September 12, 2024 / Sema Slim™, the premier online destination for effective telehealth services in…
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…
CARY, NC / ACCESSWIRE / September 12, 2024 / Yunu, a leading provider of clinical trial imaging workflow and data…
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the…
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed…
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing…
Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet…
PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma…
FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today…
On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase…